» Articles » PMID: 35840704

Quality of Life (QoL) for People with Primary Sclerosing Cholangitis (PSC): a Pragmatic Strategy for Identifying Relevant QoL Issues for Rare Disease

Overview
Specialty Health Services
Date 2022 Jul 15
PMID 35840704
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Primary sclerosing cholangitis (PSC) is a rare incurable disease of the bile ducts and liver which can significantly impair quality of life (QoL). No existing QoL tools are entirely suitable for people living with PSC (PwPSC). We aimed to develop a measure of QoL for PwPSC in the UK, beginning by identifying relevant QoL issues. This paper describes our approach to this first stage, and discusses related benefits and limitations.

Methods: Scientific consensus on how to reliably stage PSC is lacking, due to its rarity and heterogeneity. We initially hypothesised four categories for PSC severity. After beginning the study, these were revised to six. For such a rare disease, the study could not recruit sufficient participants in each of these categories, particularly the more severe, in the time available. We therefore modified the design, adapting standard methodology for identifying potentially relevant issues. We started by conducting a thematic analysis of data from a previous survey of PwPSC, and extracting QoL issues from a literature review of QoL questionnaires of relevance to PwPSC. We then conducted group and individual interviews with PwPSC and clinicians, investigating the relevance, importance, phrasing, and breadth of coverage of issues identified. We also explored the validity of our hypothesised categories for disease severity.

Results: We identified 1,052 potentially relevant QoL issues from the survey and literature review and took 396 of these forwards for discussion with 28 PwPSC. We found 168/396 issues were considered relevant by ≥ 60% of these participants. We then discussed this subset of 168 issues with 11 clinicians. PSC and clinician participants identified some problematic phrasing with 19 issues, due to potential upset (n = 12) or problems with understanding (n = 7). We included one new issue from those suggested.

Conclusion: We identified a range of QoL issues relevant to PwPSC, with a good breadth of coverage, although lacking an in-depth understanding of the PSC experience. Our strategy effectively identified relevant QoL issues for people living with this rare condition, for which there is no consensus on stratifying for its severity. This strategy should however be considered specific to such circumstances, not a general recommendation for an alternative approach.

Citing Articles

Primary sclerosing cholangitis.

Manns M, Bergquist A, Karlsen T, Levy C, Muir A, Ponsioen C Nat Rev Dis Primers. 2025; 11(1):17.

PMID: 40082445 DOI: 10.1038/s41572-025-00600-x.


What are the lived healthcare experiences of patients with primary sclerosing cholangitis? A community-based qualitative interview study.

Arndtz K, Cameron M, Hirschfield G, Parry J, Greenfield S BMJ Open. 2025; 15(2):e082498.

PMID: 39915019 PMC: 11800207. DOI: 10.1136/bmjopen-2023-082498.


Caregiver-reported symptom burden and preferences for therapeutic goals in pediatric primary sclerosing cholangitis.

Shifman H, Hatchett J, Pai R, Safer R, Gomel R, Vyas M J Pediatr Gastroenterol Nutr. 2024; 79(4):835-840.

PMID: 38899591 PMC: 11444895. DOI: 10.1002/jpn3.12287.

References
1.
Karlsen T, Vesterhus M, Boberg K . Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis. Aliment Pharmacol Ther. 2013; 39(3):282-301. DOI: 10.1111/apt.12581. View

2.
Weismuller T, Trivedi P, Bergquist A, Imam M, Lenzen H, Ponsioen C . Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology. 2017; 152(8):1975-1984.e8. PMC: 5546611. DOI: 10.1053/j.gastro.2017.02.038. View

3.
Trivedi P, Crothers H, Mytton J, Bosch S, Iqbal T, Ferguson J . Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. Gastroenterology. 2020; 159(3):915-928. DOI: 10.1053/j.gastro.2020.05.049. View

4.
Chapman M, Thorburn D, Hirschfield G, Webster G, Rushbrook S, Alexander G . British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019; 68(8):1356-1378. PMC: 6691863. DOI: 10.1136/gutjnl-2018-317993. View

5.
Trivedi P, Corpechot C, Pares A, Hirschfield G . Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. Hepatology. 2015; 63(2):644-59. PMC: 4864755. DOI: 10.1002/hep.28128. View